210 related articles for article (PubMed ID: 24096476)
1. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H
Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer.
Wu DW; Huang CC; Chang SW; Chen TH; Lee H
Cell Death Differ; 2015 May; 22(5):779-89. PubMed ID: 25323586
[TBL] [Abstract][Full Text] [Related]
3. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.
Wu DW; Chen CY; Chu CL; Lee H
Oncogene; 2016 Feb; 35(5):621-30. PubMed ID: 25915848
[TBL] [Abstract][Full Text] [Related]
4. Paxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabilization of Bcl-2 protein by phosphorylation at Serine 87.
Huang CC; Wu DW; Lin PL; Lee H
Oncotarget; 2015 Apr; 6(11):8698-708. PubMed ID: 25826088
[TBL] [Abstract][Full Text] [Related]
5. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer.
Wu HH; Wu JY; Cheng YW; Chen CY; Lee MC; Goan YG; Lee H
Clin Cancer Res; 2010 Nov; 16(21):5200-10. PubMed ID: 20959404
[TBL] [Abstract][Full Text] [Related]
6. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
8. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
[TBL] [Abstract][Full Text] [Related]
9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
10. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
11. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.
Chen MJ; Wu DW; Wang YC; Chen CY; Lee H
Sci Rep; 2016 Oct; 6():34933. PubMed ID: 27713506
[TBL] [Abstract][Full Text] [Related]
12. Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells.
Refaat A; Aminullah ; Zhou Y; Kawanishi M; Tomaru R; Abdelhamed S; Shin MS; Koizumi K; Yokoyama S; Saiki I; Sakurai H
Biochem Biophys Res Commun; 2015 Mar; 458(4):856-61. PubMed ID: 25701783
[TBL] [Abstract][Full Text] [Related]
13. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
[TBL] [Abstract][Full Text] [Related]
14. [Regulation of paxillin tyrosine phosphorylation via inhibition of c-Abl kinase to protect ventilator induce lung injury in vivo in rats].
Zhong R; Xiao J; Dai C; Yu Z
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Jul; 29(7):596-601. PubMed ID: 28743335
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
16. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting.
Wu DW; Cheng YW; Wang J; Chen CY; Lee H
Cancer Res; 2010 Dec; 70(24):10392-401. PubMed ID: 21159652
[TBL] [Abstract][Full Text] [Related]
17. Paxillin is positively correlated with the clinicopathological factors of colorectal cancer, and knockdown of Paxillin improves sensitivity to cetuximab in colorectal cancer cells.
Du C; Wang X; Zhang J; Liu X; Zhu J; Liu Y
Oncol Rep; 2016 Jan; 35(1):409-17. PubMed ID: 26530439
[TBL] [Abstract][Full Text] [Related]
18. MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway.
Chen PM; Cheng YW; Wu TC; Chen CY; Lee H
Free Radic Biol Med; 2015 Feb; 79():127-37. PubMed ID: 25499851
[TBL] [Abstract][Full Text] [Related]
19. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
20. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
